Asish K Ghosh

Calculated based on number of publications stored in Pure and citations from Scopus
Calculated based on number of publications stored in Pure and citations from Scopus
Calculated based on number of publications stored in Pure and citations from Scopus
1986 …2021

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Molecular Basis of Fibrosis: Development of Epidrug for Fibrosis Therapy.  Hyperactivity of differentiated fibroblasts causes an excessive synthesis and deposition of extracellular matrix proteins in the tissues that leads to fibrosis in multiple organs, a major cause of disease-related morbidity and mortality worldwide. Fibrosis is a common end-stage pathological symptom of a wide spectrum of injury or stress related multi-organ diseases such as hypertension-induced accelerated cardiovascular disease, chronic kidney disease, liver cirrhosis, systemic sclerosis and pulmonary disease. Epigenetics plays a key role in the development of multi-organ fibrosis. Our research interest focuses on the role of acetyltransferase p300, a major epigenetic regulator, in TGF-b-induced profibrogenic signal transduction and organ fibrosis. We have previously demonstrated that acetyltransferase p300 is an essential epigenetic regulator for profibrogenic signal-induced matrix protein collagen synthesis. Most importantly, the levels of p300 are significantly elevated in myofibroblasts derived from resident fibroblasts or vascular endothelial cells in response to TGF-beta and different fibrotic tissues. We are interested to determine i) the molecular basis of p300 elevation in fibrotic tissues; ii) the contribution of elevated level of p300 in cardiac, renal and pulmonary fibrogenesis; iii) epigenetics in cardiac and renal endothelial-to-mesenchymal transition (EndMT), cellular proliferation, migration and senescence; and iv) to develop novel epigenetic therapeutic approaches targeting acetyltransferase activity of p300 to control cardiac, renal and lung fibrosis. We are testing the therapeutic efficacies of novel small molecule inhibitors of epigenetic regulator acetyltransferase p300 for prevention and reversal of stress-induced accelerated cardiac, renal and lung aging-associated pathologies using murine models. We are also testing the efficacy of a drug-like small molecule inhibitor targeting plasminogen activator inhibitor-1 in amelioration of air pollutant PM2.5-induced lung and heart disease. The research is funded by grants from American Heart Association and National Institutes of Health.

Training Experience

1996Postdoctoral Fellowship, Chicago Medical School

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Education/Academic qualification

PhD, University of Calcutta

… → 1991

Research interests

  • Aging
  • Cardiovascular Diseases
  • Epigenetics
  • Extracellular Matrix
  • Fibrosis
  • Heart Disease
  • Hypertension
  • Cytokines
  • Drug Discovery
  • Gene Regulation
  • TGF-beta
  • Molecular Genetics
  • Vascular Biology

Fingerprint

Dive into the research topics where Asish K Ghosh is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Network

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or